- Home
- TD vs GILD Comparison
TD vs GILD Comparison
Compare TD & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TD | GILD |
|---|---|---|
| Founded | 1855 | 1987 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 157.9B | 170.9B |
| IPO Year | N/A | 1992 |
Fundamental Metrics
Financial Performance| Metric | TD | GILD |
|---|---|---|
| Price | $94.75 | $149.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 21 |
| Target Price | $120.00 | ★ $130.10 |
| AVG Volume (30 Days) | 2.1M | ★ 8.0M |
| Earning Date | 02-26-2026 | 02-10-2026 |
| Dividend Yield | ★ 3.20% | 2.12% |
| EPS Growth | 144.91 | ★ 6514.05 |
| EPS | ★ 8.25 | 6.42 |
| Revenue | ★ $45,149,067,348.00 | $29,087,000,000.00 |
| Revenue This Year | N/A | $3.66 |
| Revenue Next Year | $4.29 | $3.32 |
| P/E Ratio | ★ $11.51 | $23.26 |
| Revenue Growth | ★ 18.83 | 2.79 |
| 52 Week Low | $54.87 | $93.37 |
| 52 Week High | $96.44 | $150.50 |
Technical Indicators
Market Signals| Indicator | TD | GILD |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 80.17 |
| Support Level | $93.11 | $138.23 |
| Resistance Level | $96.03 | $141.71 |
| Average True Range (ATR) | 1.42 | 3.96 |
| MACD | -0.16 | 1.56 |
| Stochastic Oscillator | 52.65 | 95.56 |
Price Performance
Historical ComparisonAbout TD Toronto Dominion Bank (The)
Toronto-Dominion is one of Canada's two largest banks with over CAD 2 trillion in assets. TD Bank operates four business segments: Canadian personal and commercial banking, US retail banking, wealth management and insurance, and wholesale banking. The bank derives more than 50% of its revenue from Canada and has dominant market share in nearly all banking products and services. TD has around 44% of its revenue from its US operations. Its US footprint spans from Maine to Florida, with a strong presence in the Northeast.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).